INO-5401 / Inovio  >>  Phase 2
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
INO-5401 / Inovio
NCT03502785 / 2018-000309-21: INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma

Active, not recruiting
1/2
35
US
INO-5401, INO-9012, Atezolizumab, CELLECTRA™ 2000
Inovio Pharmaceuticals
Urothelial Carcinoma
12/24
12/24
NCT03491683: INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)

Checkmark From trial in combination with INO-5401 & INO-9012 for 1L GBM
Nov 2019 - Nov 2019: From trial in combination with INO-5401 & INO-9012 for 1L GBM
Active, not recruiting
1/2
52
US
INO-5401, INO-9012, Cemiplimab, REGN2810, Radiation Therapy, Temozolomide
Inovio Pharmaceuticals
Glioblastoma
12/24
12/24

Download Options